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Abstract
Adoptive cell transfer (ACT) of genetically engineered T cells expressing cancer-specific T-cell
receptors (TCR) is a promising cancer treatment. Here, we investigate the in vivo functional
activity and dynamics of the transferred cells by analyzing samples from 3 representative patients
with melanoma enrolled in a clinical trial of ACT with TCR transgenic T cells targeted against the
melanosomal antigen MART-1. The analyses included evaluating 19 secreted proteins from
individual cells from phenotypically defined T-cell subpopulations, as well as the enumeration of
T cells with TCR antigen specificity for 36 melanoma antigens. These analyses revealed the
coordinated functional dynamics of the adoptively transferred, as well as endogenous, T cells, and
the importance of highly functional T cells in dominating the antitumor immune response. This
study highlights the need to develop approaches to maintaining antitumor T-cell functionality with
the aim of increasing the long-term efficacy of TCR-engineered ACT immunotherapy.
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SIGNIFICANCE—A longitudinal functional study of adoptively transferred TCR–engineered
lymphocytes yielded revealing snapshots for understanding the changes of antitumor responses
over time in ACT immunotherapy of patients with advanced melanoma.
INTRODUCTION
A small percentage of patients with widely metastatic cancers can be cured with a variety of
immune-activating approaches. These dramatic, but infrequent, clinical responses are
generally mediated by cytotoxic T lymphocytes (CTL) that recognize tumor antigens
through their T-cell receptor (TCR). Adoptive cell transfer (ACT)–based therapies bypass
many limitations of other cancer immunotherapies by generating ex vivo and then
administering to patients large numbers of activated, tumor antigen–specific effector cells.
These cellular immune responses to cancer are mediated by CTLs specifically recognizing
tumor antigens through their TCR. Tumor antigens are of several classes, including tumor-
specific mutations, reexpressed cancer–testis antigens, and lineage-specific antigens.
Melanoma frequently expresses proteins of the pigmented pathway, reminiscent of its
normal counterpart, the melanocytes, representing lineage-specific antigens such as
tyrosinase, MART-1/Melan-A, or gp100, which have been validated as targets for T-cell
responses to melanoma (1).
Several groups have shown that the treatment of patients with ACT therapy results in a high
frequency of initial tumor responses (2–7). When using T cells with multiple antigen
specificities, such as when tumor-infiltrating lymphocytes (TIL) are used for ACT transfer,
tumor responses tend to be durable, sometimes lasting years (8). TIL therapy, however, is
feasible in only a minority of patients who can undergo surgical resection of a metastatic
lesion and who have T cells in the biopsy specimen that can be expanded in the laboratory.
A potentially more widely applicable approach is the genetic modification of T cells
obtained from peripheral blood. These blood cells can be modified to express natural TCRs
or chimeric antigen receptors (CAR) that allow the specific recognition of tumor antigens.
Early clinical experiences show that ACT using TCR-engineered T cells has antitumor
activity in patients with metastatic melanoma and sarcoma (9–11). However, most of those
responses have been transient, despite the persistence of circulating TCR transgenic cells in
many cases (9, 10). This observation raises the question of whether these cells lose their
antitumor functions or whether other components of the immune system are detrimentally
influencing the therapy. As described in patients with HIV infection, the quality of a T-cell
response is related to the functional performance of the T cells (12–14), which can be
informatively analyzed at a single-cell level with multiplexed technologies (15). Therefore,
we conducted a detailed time-course analysis of patient-derived samples, using newly
developed multidimensional and multiplexed immune monitoring assays in selected patients
receiving TCR-engineered ACT therapy (15, 16). Our analyses revealed that coordinated,
time-dependent functional changes of the adoptively transferred TCR transgenic cells and T
cells with other antigen specificities exhibited changes that paralleled the clinical outcomes
of the patients. This study highlights the need to develop therapeutic approaches to
maintaining and fostering antitumor T-cell functionality with the aim of increasing long-
term efficacy of ACT immunotherapy.
RESULTS
Clinical Protocol and Characteristics of Patients
To conduct a detailed multidimensional analysis of immune function changes over time, and
to study the response and resistance to ACT immunotherapy, we selected 3 of 14 patients
enrolled in a phase II clinical trial of MART-1 TCR transgenic ACT therapy. These 3
patients were selected on the basis of their clinical course as representative of the whole
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group, that is, an initial transient tumor response followed by progression, and also on the
basis of the adequacy of samples to be analyzed in different assay platforms. All patients
underwent a baseline leukapheresis to collect peripheral blood mononuclear cells (PBMC),
which were stimulated with anti-CD3 antibodies and interleukin (IL)-2 ex vivo for 2 days
before undergoing 2 rounds of transduction with a retroviral vector carrying the high-affinity
MART-1–specific TCR termed F5 (10). With this approach, both CD4+ and CD8+ T cells
were genetically engineered to express the MART-1–specific TCR. Cells were then cultured
in IL-2 for 3 more days and were cryopreserved after lot release testing following the
approved investigator new drug (IND) application number 13859. Once the TCR transgenic
cells were generated, patients were admitted to the hospital to receive conditioning
chemotherapy with cyclophosphamide and fludarabine (10). This lymphodepletion
procedure is designed to provide “space” within the immune system for the TCR transgenic
cells to expand, and is followed on day 0 with the reinfusion of up to 1 × 109 MART-1 TCR
transgenic cells. On the next day, and on days 14 and 30 after ACT, patients received 3
subcutaneous injections of 1 × 107 MART-126–35 peptide-pulsed dendritic cell (DC) vaccine
generated from the same baseline leukapheresis product. They also received up to 14 doses
of high-dose IL-2 at 600,000 IU/kg every 8 hours within the first 5 days after ACT (Fig. 1A;
Table 1). The lymphodepleting chemotherapy and IL-2 administration were designed to
maximize the ability of the infused TCR transgenic lymphocytes to homeostatically expand
in vivo. The MART-126–35 peptide-pulsed DC vaccine was designed to provide antigen-
specific stimulation based on our prior protocol optimization studies in mouse models (17).
The above 4 components form a combined therapy approach that provides a unified effector
mechanism—the activated tumor-specific CTLs. Details on the patients’ characteristics,
treatment delivery, and outcomes for the 3 patients (F5-1, F5-2, and F5-8) studied herein are
provided in Table 1.
The adoptively transferred TCR transgenic lymphocytes undergo a rapid in vivo expansion
and repopulate the peripheral immune system (peak frequency >50%, 90-day persistence
>10%; Table 1), with evidence of target specificity and antitumor activity (tumor reduction
of 13%–33%, Table 1 ). Repopulation of the immune system with the MART-1 TCR
transgenic T cells resulted in an initial skin rash frequently centered on moles, systemic
vitiligo (skin depigmentation) owing to attack on MART-1–specific melanocytes in the skin
and hair follicles, and diffuse infiltration of CTLs into melanoma metastases (Fig. 1B; Table
1).
Integrated Single-Cell Functional Analyses and Antigen-Specific CTL Population
Enumerations
To capture the time-dependent functional changes of the MART-1 TCR transgenic T cells
and certain other T-cell populations that could influence the therapy, we coupled our newly
developed single-cell barcode chip (SCBC; ref. 15) with multiparametric fluorescence-
activated cell sorting (FACS; Fig. 2A and Supplementary Fig. S1). This approach allowed
us to interrogate the functional performance of phenotypically defined, antigen-specific T
cells at the single-cell level. We segregated CD4+ and CD8+ T cells with MART-1
specificity, as well as MART-1− T cells with a nonnaïve phenotype, based on 10 cell-surface
parameters (Fig. 2A). We then quantitated 19 cytokines and chemokines produced from
single cells under stimulation, using the SCBC microchip platform (Supplementary Fig. S1),
expanding on the 12-cytokine panel that we had used as a pilot panel for a previous article
(15). As an initial example of the potential of our SCBC chip, in that paper, we reported the
functionality of MART-1+ T cells from patient F5-2 from study day 30 only, compared with
blood lymphocytes from 3 healthy donors. The expanded and modified new panel used
herein includes cytokines specific to CTL function (e.g., granzyme B), as well as cytokines
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characterizing Th1 (IFN-γ, IL-2), Th2 (IL-4, IL-5), Th17 (IL-17), and regulatory T (IL-10,
TGF-β) cells (Supplementary Tables S1 and S2).
We first compared the approach of FACS/SCBC with our previously described approach
that coupled single-parameter nucleic acid cell sorting (NACS) (16) with SCBC functional
analysis (15). The prior approach allowed for analysis of the MART-1 antigen–specific T
cells, but did not permit the separation of the CD8+ and CD4+ components from the mixed
population. The FACS/SCBC analysis permits such separation, but the FACS step requires a
longer time before SCBC loading, which could lead to the loss of protein signal. Therefore,
we tested the use of both antigen-specific and mitogen-based T-cell reactivation in FACS/
SCBC assays relative to antigen-specific reactivation in NACS/SCBC analyses
(Supplementary Fig. S2, Methods) using MART-1+ T cells from a patient (F5-8) who had
few CD4+ MART-1+ T cells. Both protocols revealed similar cytokine secretion profiles and
time-dependent functional changes, within the range of error bars. Thus, although some
signal loss may be associated with the FACS/SCBC assays, much of the critical information
content is retained, and the significantly improved phenotype selection is a powerful
advantage.
The CD8+ MART-1− T-cell population may contain populations that are specific to
melanoma antigens other than MART-1. The detection of such populations has been
attributed to epitope spreading, where T cells with antigen specificity other than the one
induced by vaccination or ACT appear after tissue damage by the driver clone (18). Thus,
we also monitored the frequency of 35 antigen-specific subpopulations against the
previously described putative melanoma tumor antigens (Supplementary Table S3) using the
NACS peptide/MHC tetramer assays (16). We also conducted multiplexed blood molecular
marker assays based on samples from this clinical trial (Supplementary Fig. S1). The results
will be reported separately.
General Properties of T-cell Functional Changes Observed in ACT
The 19 measured cytokines and chemokines studied represent a broad range of T-cell
functions (Fig. 2B). To capture general trends, we conducted hierarchical clustering of each
T-cell type studied on the basis of SCBC data from the 3 patients and all time points (Fig.
2B; Supplementary Table S2). For the CD8+ MART-1+ T cells, we observed a primary
clustering into antitumor effector functions (granzyme B, TNF-α, IFN-γ, etc.). Additional
functions, such as regulatory (IL-10, TGF-β2) and proinflammatory (IL-6, IL-1β), are
resolved with additional clustering ( Fig. 2B ). Further analysis revealed that proteins within
the same functional group exhibited a higher correlation than with proteins outside that
group (Fig. 2B bottom). These functional groupings are largely conserved across the 4 cell
types studied (Supplementary Table S2). Thus, the T cells that we studied tend to exhibit
coordinated behaviors.
The cytokine readouts that we measured reflect the kinetics of the immune response process.
As an example, Fig. 2C and Supplementary Fig. S3 present one-dimensional scatterplots of
the cytokine production intensity of single CD8+ MART-1+ T cells from patient F5-1 over
time. Supplementary Figure S4 shows such changes for patients F5-2 and F5-8. Gates that
separate protein-secreting and nonsecreting cells are identified by comparing signals from
empty chambers and one-cell chambers. The percentage and mean fluorescence intensity
(MFI) of granzyme B–producing cells decreased sharply within the first 30 days after ACT,
whereas IFN-γ (Fig. 2C ) and TNF-α (Supplementary Fig. S3) were most abundant at day
60. The chemokines MIP-1a (Fig. 2C) and MIP-1b (Supplementary Fig. S3) reflected time-
course features of both granzyme B and IFN-γ. Of note, IL-2 secretion remained low (<3%
positive cells) across all time points (Supplementary Fig. S3). The total functional intensity
for a given cytokine (defined as % positive cells × MFI, and plotted as the black line in Fig.
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2C) reveals again these 2 waves of the immune response after ACT, characterized by the
production of granzyme B, IFN-γ, and TNF-α. In addition, unique functional properties of
the cell types studied are reflected in the cytokine measurements: 3 of the 4 cell types
studied could be easily distinguished on the basis of their cytokine profiles (Supplementary
Fig. S5).
We noted that higher protein production levels were associated with cells that exhibit a
higher polyfunctionality (Fig. 2C). This feature is also quantitatively summarized in Fig. 2D
and Supplementary Table S4 for all measured cytokines, where we defined a polyfunctional
cell as one producing 5 or more cytokines upon stimulation. Such cells typically make up
only 10% of the population of a given cell type, but on average, they secrete 100 times more
copies of a given protein than do the remaining 90% of the population (Fig. 2D). The
inference is that the highly functional T cells dominate (by about 10-fold) the antitumor
immune response.
On the basis of the importance of the polyfunctional T cells, we defined a polyfunctional
strength index (pSI) for summarizing the observed T-cell functional changes. For a given
cell type, the pSI is calculated as the percentage of polyfunctional T cells relative to all
CD3+ T cells, multiplied by the sum of the MFI of each of the 19 assayed cytokines from the
polyfunctional subset. This index represents the total functional intensity contributed by all
polyfunctional T cells of a given cell type, at a specific time point. We further characterized
pSI according to the types of coordinated functions that are revealed through cytokine
clustering.
Time-Dependent Functional Changes
We analyzed the samples from 3 patients to compare the functional dynamics of the CD8+
MART-1+ T cells (using the pSI) against the frequency and phenotypic changes of these
cells, as well as changes in tumor burden (Fig. 3). All 3 patients exhibited an initial
reduction in tumor volume, followed by tumor regrowth, but with different times to tumor
relapse (Fig. 3A). In contrast, the patients had evidence of engraftment of the TCR-
engineered cells (Fig. 3B). The cells proliferated briskly following ACT by at least one log
expansion in total cell numbers, and then diminished gradually. At least 109 MART-1+ T
cells, which accounted for more than 10% of blood T lymphocytes, remained in circulation
out to day 90 after ACT. The cellular phenotyping, based upon cell-surface marker
expression, revealed relatively uniform changes among the 3 patients, from an early
differentiation phenotype (naïve, central memory, and effector memory) to a later
differentiation phenotype (effector memory RA and effector; Fig. 3C, Methods, and
Supplementary Table S5).
These observations contrast with the functional changes recorded for polyfunctional T cells,
as represented by the pSI plots of Fig. 3D. These plots reveal large-amplitude functional
changes as well as clear differences between the patients. For F5-1, at day 7 after ACT, the
CD8+ MART-1+ T cells predominantly produced the cytotoxic molecule granzyme B, which
accounted for more than 70% of the total functional intensity. However, by day 30, the pSI
of these cells declined by about 100-fold. The functional strength of these cells begins to
recover by day 45, but that recovery is accompanied by a different set of functions,
including TNF-α, IFN-γ, and inflammatory cytokines (such as IL-6), with no cytotoxic
granule production. For F5-2, the CD8+ MART-1+ T cells exhibited high antitumor effector
functions (IFN-γ and TNF-α) only after day 30. Patient F5-8 exhibited strong antitumor
functions (granzyme B, IFN-γ, and TNF-α) initially that rapidly declined by day 30 after
ACT.
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The functional behavior of the other profiled T-cell types also exhibited sharp dynamic
changes. We present such data for patient F5-1 in Fig. 4A–F. Functional changes for patients
F5-2 and F5-8 are shown in Supplementary Figs. S6 and S7. A table that summarizes
changes between day 60 and day 07 for the 3 patients is provided in Fig. 4G. The pSI of
CD4+ MART-1+ T cells drops by approximately 100-fold at day 7 after ACT and shows an
unstable functional profile, switching from proliferative-dominant (IL-2) at day 0; to
antitumor effector-dominant (IFN-γ, TNF-α) on day 7; to inflammatory, regulatory, and
nonspecific-dominant on day 30 ( Fig. 4A). We also recorded an accelerated disappearance
of these cells when compared with the CD8+ MART-1+ T cells (Fig. 4B). A similar decrease
in the pSI with functional shifting was observed for patient F5-8 (Supplementary Fig. S7 and
Fig. 4G ). For F5-2, no cytokine production from this T-cell population was detected. Thus,
this group of unnatural T cells—CD4+ T cells expressing TCRs recognizing a MHC class I–
restricted antigen—lacked the ability to proliferate and conduct stable functions in vivo.
The lymphodepletion and subsequent recovery process is reflected in the time-dependent
functional changes of the MART-1− T cells (Fig. 4C–F). For CD8+ MART-1− T cells from
patient F5-1, the composition of the pSI is relatively unchanged across the 90-day period
after ACT, and exhibits cytotoxic and other antitumor functions throughout (Fig. 4C). At
about day 30 after ACT, 4 populations attributable to epitope spreading were detected (Fig.
4D). The presence of these populations was transient, diminishing again by day 72 after
ACT. Patient F5-2 presented similarities to F5-1. For example, similar epitope-spreading
dynamics and a durable, antitumor effector function–dominant pSI were both recorded for
the CD8+ MART-1− T-cell population for F5-2 (Fig. 4G and Supplementary Fig. S6). In
contrast, patient F5-8, who had the lowest level of antitumor response, as well as a rapid
tumor relapse (Fig. 4G; Table 1), presented no evidence of epitope spreading and only a
transient antitumor pSI that had diminished by day 30 after ACT (Fig. 4A and
Supplementary Fig. S7).
In patient F5-1, the pSI of the CD4+ MART-1− T cells diminished during lymphodepletion
preconditioning and recovered by day 45. In absolute amplitude, the functional composition
of these cells was relatively constant and was dominated by proliferative functions (such as
IL-2 and GM-CSF Fig. 4E). However, starting about days 30 to 45, regulatory functions
(TGF-β and IL-10) increased most significantly (by 27-fold relative to day 7; Fig. 4F and
G). This strong increase of regulatory functions in these non–TCR transgenic T cells was
also noted in samples from patient F5-8, as well, at approximately day 60 (Fig. 4G and
Supplementary Fig. S7).
DISCUSSION
Little is known about the mechanisms that lead to tumor progression after a response in
patients receiving ACT immunotherapy. For many years, the prevailing concepts were based
on the outgrowth of tumor escape variants that down-regulated the expression of tumor
antigens or molecules of the antigen-expressing machinery, or the preexistence of mutant
clones that were insensitive to immune cell attack (19). More recently, several experiences
are pointing to direct adaptive responses of tumors resulting from modulation of the tumor
target by the T cells themselves, with the tumors changing through a variety of mechanisms
to become insensitive to the CTL attack. Examples include the upregulation of PD-L1 (B7-
H1) in response to IFNs produced by tumor-infiltrating T cells (20), and the antigen-specific
T cells producing cytokines (i.e., TNF-α) that result in melanoma cells that express
melanosomal antigens to dedifferentiate so that they may escape (21). These are cancer cell
intrinsic mechanisms of resistance in response to adequately activated tumor antigen–
specific T cells with full effector functions. A series of cancer cell extrinsic mechanisms of
resistance to immunotherapy have also been postulated, with a major focus on the presence
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of immune-suppressive cells in tumors. The role of regulatory T cells, indoleamine 2,3-
dioxygenase–positive DCs, and myeloid-derived suppressor cells in dampening immune
responses in tumors has been well established in animal model systems and in patient-
derived samples (22). Some of these immune-suppressive cells are attracted or activated by
the tumor-mediated secretion of immune-suppressive factors, such as the TGF-β, VEGF,
and certain other chemokines.
The study of immune cell intrinsic mechanisms of resistance has been limited by the
complexity of repeatedly assaying immune functions over time, and has typically relied on
assays quantifying the frequency of tumor-specific T cells, analysis of a single effector
molecule, or analyses of surface proteins for identifying different T-cell phenotypes.
However, T cells produce a large amount of coordinated proteins in response to antigen
recognition, and that immune response, in terms of breadth and depth, is guided by the
spectrum and level of the proteins being produced (12). For example, it has been previously
shown in mouse models that the functional behavior of polyfunctional T cells best reflects
the overall quality of an immune response (23), presumably because multiple T-cell
functions are needed to orchestrate a successful immune response.
In the current studies, we interrogated T-cell responses to cancer by applying new-
generation, multiplexed immune monitoring assays. These assays yield an unprecedented
high-resolution view of T-cell functional dynamics in patient-derived samples. These are
highly involved studies, and so we focused on extensively analyzing samples from 3 patients
who exhibited different degrees of tumor response after ACT immunotherapy. Our studies
suggest that occurring initially is a wave of cytotoxicity-dominated antitumor functions from
adoptively transferred CD8+ MART-1–specific T cells. This wave leads to initial melanoma
tissue destruction, as detected by a decrease in the size of the metastatic lesions. As has been
noted in autoimmune diseases, this initial tissue destruction can lead to the expansion of T
cells, with specificity for other melanoma antigens or epitope spreading (18). Epitope
spreading within the population of the CD8+ MART-1− T cells was detected about day 30 in
the 2 patients who had the best tumor responses, and that population of T cells retained
robust antitumor functions out to at least day 90. However, the frequency of tumor-specific
CTLs induced by epitope spreading was not maintained. One possibility, consistent with the
data reported here, is that the CD4+ T cells, as they recover from the lymphodepletion
regimen, may regulate and inhibit the antitumor immune response. This idea is also
consistent with a report indicating that a deeper lymphodepletion regimen can improve the
outcome for melanoma patients participating in TIL-based ACT trials (24).
A number of factors based on properties of cell phenotype and persistence that are
associated with ACT therapy efficacy have been identified (8, 25). Our study supports the
notion that T-cell function is another important aspect that requires close scrutiny; even
when T cells show similar persistence and phenotypic changes in vivo, they can exhibit
dramatically different functional profiles. Although the number of patients in this study was
limited, each of the patients was very thoroughly investigated, to the extent that we can
begin to associate some of the functional changes with differences in tumor relapse between
patients. As shown in Fig. 4G, a strong gain (day 60 compared with day 7) of IFN-γ and
TNF-α for CD8+ MART-1+ T cells, granzyme B and IFN-γ for CD8+ MART-1− T cells,
antitumor effector and proliferative functions for CD4+ MART-1− T cells, and a wider
epitope spreading are, at least for this study, associated with a slower tumor relapse. In
contrast, a strong gain of regulatory functions in CD4+ MART-1− T cells following their
recovery from the lymphodepletion regimen seems to be associated with a corresponding
faster tumor relapse (Fig. 4G).
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These results suggest the need to incorporate strategies to maintain the functional properties
of the TCR transgenic cells used for ACT therapies. These may include modifications of the
culturing system to foster the generation of TCR transgenic cells with improved ability to
persist functionally over time ( 26 ), pharmacologic manipulations to provide more
prolonged γ-chain cytokine support (such as protracted low-dose IL-2 administration),
blockage of negative costimulatory signaling like CTLA4 or PD-1, or additional genetic
engineering of the TCR transgenic cells to include cytokines or transcription factors that
could maintain their function in vivo. It is also clear that the endogenous T cells can expand
and boost the antitumor immune response and can regulate or otherwise influence the
function of the infused T cells. Understanding this biology, and learning to control it, seems
to be an important research direction for ACT therapy. A broader application of these single-
cell functional analyses may prove valuable for probing the successes and failures across the
spectrum of cellular immunotherapies. In particular, recent ACT trials that have used either
engineered TCRs or CARs directed against antigens with better tumor selectivity than
MART-1 have resulted in cases showing complete regression ( 2, 11 ). Directing the tools
described herein toward analyzing those successes may provide powerful insights into how
best to design such therapies.
METHODS
ClinicalTrial Conduct
Patients were enrolled in the clinical trial after signing a written informed consent approved
by the University of California, Los Angeles [UCLA, Los Angeles, CA; IRB (08-02-020
and 10-001212) under an IND filed with the U.S. Food and Drug Administration (IND
13859)]. The study had the clinical trial registration number NCT00910650. Eligible
patients had MART-1+ metastatic melanoma by IHC and were HLA-A*0201 positive by
intermediate-resolution molecular HLA testing. Objective clinical responses were recorded
following a modified Response Evaluation Criteria in Solid Tumors (RECIST; ref. 27), in
which tumor burden is quantified by the sum of the largest diameter of each tumor lesion
measured either by PET/ CT scan or physical examination. Skin and subcutaneous lesions
evaluable only by physical examination were considered measurable if adequately recorded
using a photographic camera with a measuring tape or ruler; no minimum size restriction
was established for these lesions.
Immunophenotyping and Immunohistochemistry
Calculation of the absolute number of blood circulating MART-1 tetramer-specific T cells
was conducted by a dual-platform method, combining the readout from flow cytometry and
automated hematology analyzer (28). The flow cytometry–based MHC tetramer assay
studies and the adaptation of a multicolor flow cytometry have also been previously
described (29–31). T cells were classified using a panel of antibodies as described in
Supplementary Table S5. Naïve cells were classified as CD45+/CCR7+/CCR5−/PD1−,
CD27+/ CD28−/CD62L+, and CD45+/CCR7+/CCR5−/PD1+; central memory as CD45RO−/
CD25−/HLA-DR−/CD127+; effector memory as CD45−/ CCR7−/CCR5+/PD1+, CD45−/
CCR7−/CCR5−/PD1+, CD45−/CCR7−/ CCR5−/PD1−, CD45−/CCR7−/CCR5−/PD1−, and
CD27−/CD28−/ CD62L−; effector memory RA (EMRA) in CD8+ as CD45RA+/CCR7−/
CCR5−/PD1+, and CD45RA+/CCR7−/CCR5+/PD1+; and effector as CD45RO+/CD25+/
HLA-DR+/CD127−, CD45RO+/CD25+/HLA-DR−/CD127−, and CD45RO+/CD25−/HLA-
DR−/CD127− (32, 33). Immunohistochemical staining was conducted following standard
methods as previously described (34, 35).
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Enumeration of Antigen-Specific T Cells
Our previously described peptide/MHC tetramer cell sorting approach (NACS) was used to
enumerate antigen-specific T cells from cryopreserved PBMCs obtained from patients
through peripheral blood draws and leukaperesis, as we have previously described (16).
Briefly, NACS chips were generated by incubating p/MHC tetramer–ssDNA conjugate
cocktail for 1 hour. Then 1 million PBMCs were added on the chip in RPMI medium for 20
minutes. Later, the slide was washed with RPMI medium and stained with CD3, CD4, and
CD8 antibody cocktail for 30 minutes. Then, the sample was fixed with paraformaldehyde /
PBS buffer for imaging with a Nikon TI fluorescence microscope. The p/MHC tetramer was
manufactured in-house. The method was shown to have good assay performance in
comparison with flow cytometry analysis (ref. 16; Supplementary Fig. S8). The sensitivity
of these NACS arrays in detecting a particular tumor antigen–specific T-cell population
from all CD3+ T cells is approximately 0.1% (16).
Purification of Phenotypically Defined T Cells
We used 2 methods to purify T cells for SCBC functional assays. For the NACS/SCBC
protocol, the MART-1+ or CD3+ cells were purified using p/MHC tetramer or CD3
antibody, as described above. Then cells were released and loaded on the SCBC chip within
30 minutes with MART-1 tetramer/CD28 antibody (10−7 mol/L and 2 μg/mL, respectively;
ref. 36) or CD3/CD28 antibody (10 and 2 μg/mL, respectively) stimulation.
For the FACS/SCBC protocol, the T cells were sorted using a BD Aria II machine. Cells
were gated on FSC-A, FSC-H, SSC-A (for singlet, lymphocyte identification), 7-AAD
(viability), CD3 (clone: UCHT-1), CD4 (OKT-4), CD8 (HIT8a), MART-1 tetramer,
CD45RA (HI100), and CCR7 (G043H7). The machine was calibrated with BD -positive and
-negative CompBeads before use. Before sorting, PBMCs had a viability of more than 80%,
and the 4 collected T-cell populations were gated to achieve more than 95% viability and
purity. The following cell populations were sorted and analyzed: CD3+CD4+MART-1+,
CD3+CD8+MART-1+, CD3+CD4+ nonnaïve MART-1−, and CD3+CD8+ nonnaïve
MART-1−. Naïve T cells were classified as CD45RA+ and CCR7+. Then, the cells were
washed before stimulation with MART-1 tetramer/CD28 antibody, MART-1 tetramer, CD3/
CD28 antibodies, and CD3 antibody, respectively. The concentrations used were as follows:
MART-1 tetramer (10−7 mol/L; ref. 36), CD3 antibody (10 μg/mL), and CD28 antibody (2
μg/mL). All cell samples were also nonspecifically stimulated with phorbol 12-myristate 13-
acetate (PMA; 5 ng/mL) and ionomycin (500 ng/mL), given the long time and low-
concentration staining required for FACS previously on chip functional assays that may lead
to a low level of spontaneous cytokine production. However, these could be recovered by
mitogen stimulation, as shown in Supplementary Fig. S2.
Integrated Functional Assays of Single T Cells
We integrated upstream cell purification techniques with the SCBC (15) to enable the study
of the functional proteomics from phenotypically defined single cells. The chips used here
had a capacity of 1,360 microchambers, and permitted the simultaneous measurement of 19
cytokines from single cells. The chip was first blocked with 3% bovine serum albumin
(BSA)/PBS buffer before hybridizing with antibody–DNA cocktails (15). Each step takes an
hour. After PMBCs were stimulated and loaded onto an SCBC chip, the chip was imaged
using high-resolution bright field microscopy. Cells were incubated on the chip for 12 hours
at 37°C in a 5% CO2 cell incubator. Then they were rapidly washed out. The assay was
completed by applying secondary biotinylated antibodies and streptavidin-Cy3 and then a
final wash with 3% BSA/PBS buffer in sequence. Every step in this part of the process also
takes an hour. Finally, the slide was washed with PBS and 50/50 PBS/deionized water in
sequence before spin drying and scanning by a GenePix 4400A scanner (Molecular
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Devices). Detailed calibration and validation have been provided previously, where the
measurement accuracy (coefficient of variation) of any given protein within a single-cell
assay is approximately 10% (15) and the assay sensitivity is several hundred molecules (15).
Computational Algorithm and Statistical Analysis
Custom routines written in the R software package were used to process, analyze, and
visualize the single-cell functional assay results. The algorithm converts original scanned
fluorescence images into data files containing the fluorescence intensities for each assayed
protein within a given microchamber, and then matches them with the number of cells
counted from videos of the chip collected. Data from empty chambers are used to measure
the background level for each protein. These data were used to generate protein abundance
histograms, which are fitted by normal distributions and nonparametric methods, judged by
goodness of fit (37). The mean of the histogram, identified by the best fit, is used as the
background level. Single-cell data were then normalized by subtracting this background, so
that different samples can be compared. The single-cell data were then fitted by finite
mixture models, and the gate that separates the cytokine-producing and non–cytokine-
producing cells was identified (37, 38). To ensure robustness, the results were individually
checked. These data were then used for subsequent hierarchical clustering and principal
component analysis (38), as well as the analysis of the pSI of the cells. Statistics and visual
presentation were automatically generated by the algorithm.
The pSI is defined as the total functional intensity contributed by all polyfunctional T cells
of a given cell type, at a specific time point. Therefore, for a given cell type, the pSI is
calculated as the percentage (%) of polyfunctional T cells relative to all CD3+ T cells,
multiplied by the sum of the MFI of each of the 19 assayed cytokines from the
polyfunctional subset, that is,
Then, we further plot pSI as a segmented bar showing the contribution of each group of
cytokines identified by hierarchical clustering. When comparing polyfunctional T cells with
other T cells, fluorescence intensity is converted into molecular number, using the
calibration curves provided in ref. 15.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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MART-1TCR transgenic T-cell ACT therapy. A, the boxes above the timeline show
different modules of the therapy, with arrows pointing to the time they are administered
relative to day 0 (the day of the infusion of the TCR-engineered T cells). Arrows below the
timeline show the dates when blood samples are collected for different assays. B, photo of
one representative patient’s back with skin rash surrounding moles (top). In the
immunohistochemical (IHC) staining of a tumor biopsy (bottom), CD8+ CTLs are stained as
dark brown and melanoma cells are blue. PET/CT, positron emission tomography/computed
tomography.
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FACS scheme for purifying phenotypically defined T cells and general properties of T-cell
functions. A, multiparametric FACS purification for selecting phenotypically defined T-cell
populations. A representative set of scatterplots is shown with the surface markers used and
the cell frequency for each gating. B, hierarchical clustering of the 19 functional cytokines
studied on the basis of the single-cell cytokine secretion measurement of CD8+ MART-1+ T
cells from all 3 patients, and across all time points. Each functional group is identified and
labeled (red). Protein–protein correlations for proteins within the same group and across
groups are given below the clustering map. C, one-dimensional scatterplots of 3
representative cytokines produced by single cells, separated by time points. The dotted line
represents the gate that separates cytokine-producing and nonproducing cells. The
percentages given above the plots denote the frequency of positive cells and the relative
mean fluorescence intensity (MFI) of those cells relative to day 7. Each point represents a
single-cell assay. The points are color encoded (from purple to red) to represent the number
of different proteins produced by each cell. The black trend line shows the total functional
intensity of the positive cells for the specific cytokine plotted, computed as the frequency of
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positive cells, multiplied by their MFI. D, ratio between the MFI (red line) and the
molecular number of cytokines (blue line) for polyfunctional T cells (cells with 5 or more
functions) and all other cells, for each cytokine. At far right are the mean and median values,
averaged over all cytokines. 7-AAD, 7-aminoactinomycin D; CCL, CC chemokine ligand;
FSC, forward scatter; GM-CSF, granulocyte macrophage colony-stimulating factor; MIP,
macrophage-inflammatory protein; SSC, side scatter.
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Time-dependent changes in tumor burden, and in number, phenotype, and function of CD8+
MART-1+ T cells. Each row provides results for a different patient (F5-1, F5-2, and F5-8).
A, changes in tumor burden, as measured by a modified RECIST method (see Methods). B,
changes of frequency (blue) and total number (green insert) of CD8+ MART-1+ T cells. C,
phenotypic changes of CD8+ MART-1+ T cells. The percentage of each T-cell phenotype
(naïve, central memory, effector memory, effector memory RA, effector) is represented by a
different color. D, functional changes (in pSI) of CD8+ MART-1+ T cells. Each cytokine
function group is represented by a different color. For F5-2 and F5-8, the y-axis is
discontinuous to allow for representation of large functional differences on the same graph.
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Functional changes of other T-cell types for patient F5-1 over time and a summary of
functional changes for all 3 patients. A, functional changes of the CD4+ MART-1+ T cells,
plotted as a bar graph in pSI. The total frequency of this phenotype is plotted as the orange
background. Each cytokine function group is represented by a different color. The percent
composition of the functions is provided in the inset. B, the frequency ratio of CD4+
MART-1+ to CD8+ MART-1+ T cells. C, functional changes of the CD8+ MART-1− T cells,
with cell frequency presented as the orange background. D, frequency of antigen-specific T
cells recognizing melanoma antigen other than MART-1 over the course of the therapy. The
total frequency is plotted as the black line to provide an overall view of epitope spreading.
The frequency of each antigen specificity detected is provided in the inset, denoted by
different colors. E, functional changes of the CD4+ MART-1− T cells, with cell frequency
presented as the orange background. F, relative functional changes of the CD4+ MART-1− T
cells normalized to those observed at day 7 by each cytokine group, along with cell
frequency. G, a summary of functional changes for each T-cell type analyzed across 3
patients. The ratio is calculated by the pSI for a cytokine functional group at day 60 relative
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to that at day 7. The patients are ordered according to increasing tumor relapse rate. The
differences between patients in cell function (solid blue shapes) and in tumor burden (red
shapes) are shown graphically in the table.
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